Cyclopamine

For research use only.

Catalog No.S1146 Synonyms: 11-deoxojervine

71 publications

Cyclopamine Chemical Structure

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cyclopamine has been cited by 71 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NHfKSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTVwOE[2OkDPxE1? MXrTRW5ITVJ?
DOHH-2 NHL3WoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfIfoVEUUN3ME25MlM2Pjh7IN88US=> MkH3V2FPT0WU
no-10 M1K5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\tWWlEPTB;OT65NFM6KM7:TR?= MkHiV2FPT0WU
LS-513 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTITWM2OD1zMT6zOVQ4KM7:TR?= M1;K[nNCVkeHUh?=
ALL-PO M3frRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFzLke3N|Qh|ryP M{DqfnNCVkeHUh?=
8-MG-BA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\UWHg6UUN3ME2xN{4yOTJ|IN88US=> NGXsbXFUSU6JRWK=
RPMI-8402 M4nZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK5TWM2OD1zNT64OVM4KM7:TR?= NFvFcINUSU6JRWK=
EoL-1-cell NXS0bWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHPTWM2OD1zOD61PVQ5KM7:TR?= NVLMZmY1W0GQR1XS
NALM-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF7LkCxOlch|ryP M{[yR3NCVkeHUh?=
DEL NYq5R2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXFcIROUUN3ME2yNE4yPDdzIN88US=> NWLwbpFKW0GQR1XS
SR NVTIeYZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTjWZVZUUN3ME2yN{43PzF3IN88US=> MX3TRW5ITVJ?
697 M3jvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nOe2lEPTB;Mk[uOlE2PSEQvF2= MUnTRW5ITVJ?
COLO-829 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDaTWM2OD1{Nj64OFg{KM7:TR?= MkXpV2FPT0WU
EVSA-T NUTPc45QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnofoVKSzVyPUK3MlU2PjFizszN NHj3O|dUSU6JRWK=
ATN-1 M2C2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLpTWM2OD1|MT6yN|I6KM7:TR?= Ml7jV2FPT0WU
L-363 M2joZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\k[YdKSzVyPUOxMlc1PjFizszN NHTsfXRUSU6JRWK=
LAMA-84 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjYelRJUUN3ME2zNk42OjFzIN88US=> MX7TRW5ITVJ?
NOS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTN2LkK5OVYh|ryP M1zZeXNCVkeHUh?=
BB30-HNC NXnzZm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPOZXpvUUN3ME2zOE4{OzB4IN88US=> MXXTRW5ITVJ?
BC-1 NGnxepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfUbXJXUUN3ME2zO{46PzR4IN88US=> M33aXHNCVkeHUh?=
IST-SL2 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rib2lEPTB;M{iuNlI1KM7:TR?= M1nmeHNCVkeHUh?=
D-392MG NGLWToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3zTWM2OD12MD6yNlE2KM7:TR?= Ml3CV2FPT0WU
no-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn3fHpKSzVyPUSwMlU2OjFizszN MlXOV2FPT0WU
LC4-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRyLki3NVYh|ryP MYnTRW5ITVJ?
A388 NG[we2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXzTWM2OD12Mj61PFQ5KM7:TR?= NEXBRXRUSU6JRWK=
NTERA-S-cl-D1 NXvwO4NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KxUmlEPTB;NEKuO|A4PCEQvF2= NF;lXnNUSU6JRWK=
CESS MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:yNm9VUUN3ME20OE4zOjN{IN88US=> NXnaUlIzW0GQR1XS
RS4-11 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnmTG9KSzVyPUS5MlA6OzhizszN M2DQNHNCVkeHUh?=
MS-1 NGnOUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr6UFZRUUN3ME21NE46OzVzIN88US=> NETUS4RUSU6JRWK=
CTV-1 M3jLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T3cGlEPTB;NUGuNFc1KM7:TR?= NV\SbnpJW0GQR1XS
D-502MG NWDoVYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP2SmxKSzVyPUWxMlYzPzFizszN NIjZempUSU6JRWK=
ML-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDWVVVKSzVyPUWyMlkyQTVizszN NGTKVWJUSU6JRWK=
SK-NEP-1 NFfkZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTV|LkO5NlMh|ryP NFj0WYxUSU6JRWK=
LOXIMVI M1HHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTV|LkW4PFQh|ryP MoWzV2FPT0WU
DJM-1 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3MOFVKSzVyPUW2MlM{QTFizszN MYLTRW5ITVJ?
GI-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTV4Lk[xOFkh|ryP MlzxV2FPT0WU
IST-MES1 NWnNW|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLLTWM2OD14MD61OFk{KM7:TR?= NWS3SIFtW0GQR1XS
MV-4-11 M122Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e4V2lEPTB;NkCuOlU{QCEQvF2= NE\DR4tUSU6JRWK=
OVCAR-4 NEP0XG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT5NIN7UUN3ME22N{42PjV5IN88US=> NWe4OnRRW0GQR1XS
KE-37 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHQdo0zUUN3ME22Ok4zPjZ6IN88US=> MXnTRW5ITVJ?
D-542MG NW[5cIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy1NoxZUUN3ME22PE41OTN3IN88US=> NHfo[pJUSU6JRWK=
MHH-PREB-1 M{XYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHmTWM2OD15Mj64OFQyKM7:TR?= M1vmPHNCVkeHUh?=
MRK-nu-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLlTWM2OD15Mz60O|A2KM7:TR?= MkDTV2FPT0WU
D-247MG M{jNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Dpb2lEPTB;N{OuOVQ1OiEQvF2= M1PrO3NCVkeHUh?=
OCI-AML2 NWDHV4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTd4LkmzOlkh|ryP M2LzNXNCVkeHUh?=
LP-1 NVPl[opXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTh{Lki3N|Eh|ryP MYPTRW5ITVJ?
HCC1599 NX3uUXpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTh2LkK4N|ch|ryP MkDlV2FPT0WU
KARPAS-45 NFH1THhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfneGNkUUN3ME24OE43QTl{IN88US=> MonLV2FPT0WU
BE-13 NVG4doljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonsTWM2OD17OT6wOFc4KM7:TR?= MoHUV2FPT0WU
GCIY M{j1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vWdmlEPTB;OUmuNFk2PCEQvF2= M321NnNCVkeHUh?=
BV-173 M4jN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfJ[GFPUUN3ME2xNFAvOzJ3IN88US=> NWXFU|d5W0GQR1XS
LB2518-MEL MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[0dmlEPTB;MUCwMlc5QSEQvF2= M2LFZ3NCVkeHUh?=
KS-1 M3TLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL5c2lKSzVyPUGwNU43OzlizszN MWrTRW5ITVJ?
MOLT-16 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle2TWM2OD1zMESuPVg3KM7:TR?= Ml3VV2FPT0WU
NCI-H1770 NG\CeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFyOD63PFQh|ryP MUPTRW5ITVJ?
NCI-H82 NGnQV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e1ZmlEPTB;MUGwMlk4PiEQvF2= M3HKd3NCVkeHUh?=
NCCIT NInNfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHpT4R5UUN3ME2xNVIvPTJ7IN88US=> NG\tUYFUSU6JRWK=
KALS-1 NWLUeY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOxTWM2OD1zMUWuPVQyKM7:TR?= M3LCenNCVkeHUh?=
LB2241-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXficJJEUUN3ME2xNVYvPjd7IN88US=> MXzTRW5ITVJ?
HH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzP[|RjUUN3ME2xNVcvOzl3IN88US=> NIDxeHlUSU6JRWK=
HD-MY-Z NX63cZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlntTWM2OD1zMUiuOFg5KM7:TR?= MkXUV2FPT0WU
EB-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr4TWM2OD1zMkOuNFk1KM7:TR?= NFy2eJlUSU6JRWK=
BL-70 M{nvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF{Mz6xNlch|ryP Ml;mV2FPT0WU
K-562 NHP2cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF{Nj6yOFUh|ryP MXrTRW5ITVJ?
HT-144 M3vq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS1eo9KUUN3ME2xN|MvOTZ2IN88US=> NIHZb2lUSU6JRWK=
PF-382 NF:xSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ONolKSzVyPUGzOE4{PjFizszN M3LlbnNCVkeHUh?=
RPMI-8226 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nDZ2lEPTB;MUO1MlA1PSEQvF2= NEDzWllUSU6JRWK=
NCI-H1355 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXNTWM2OD1zM{WuOVg4KM7:TR?= MXXTRW5ITVJ?
LXF-289 NEDmeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF|OT63PFEh|ryP NEmxfG5USU6JRWK=
NCI-H69 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrMSFhKSzVyPUG0Nk46OzJizszN NI\EPGFUSU6JRWK=
SK-MEL-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL5TWM2OD1zNEeuNVMh|ryP MorkV2FPT0WU
KARPAS-299 NV3tR5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLiTWM2OD1zNEmuNVIh|ryP M17Ld3NCVkeHUh?=
GB-1 NFG0clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF2OT6zNlIh|ryP NWLOenBXW0GQR1XS
CMK MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIWwZpJKSzVyPUG0PU42OTVizszN M1TNXXNCVkeHUh?=
MPP-89 NYqxZ|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHMUVFIUUN3ME2xOVYvODN3IN88US=> NGLNOZhUSU6JRWK=
KU812 M3WyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqyTWM2OD1zNkGuPVAzKM7:TR?= NW\hVHdJW0GQR1XS
REH NGjObY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K5bGlEPTB;MU[yMlEzPSEQvF2= M3\2SnNCVkeHUh?=
NEC8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[zXnZKSzVyPUG2OU4xOjZizszN NUDUdGJZW0GQR1XS
KP-N-YS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjRT5ZKSzVyPUG2PE4{QTVizszN M3T3U3NCVkeHUh?=
Ramos-2G6-4C10 NGDtc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HKXmlEPTB;MU[5MlkyPSEQvF2= NGHY[JpUSU6JRWK=
Becker MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF5ND6xPEDPxE1? NVvXNYpxW0GQR1XS
LB647-SCLC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvMXoJKSzVyPUG3OU45PDVizszN M2mybXNCVkeHUh?=
LU-139 NWrnWGp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPYTWM2OD1zN{iuNFE6KM7:TR?= M3PBNHNCVkeHUh?=
QIMR-WIL NW\tOY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjGTnhkUUN3ME2xO|kvPjR4IN88US=> M{PDUnNCVkeHUh?=
NCI-H1395 M{PGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q2UGlEPTB;MUe5Mlk6PiEQvF2= M2Wye3NCVkeHUh?=
NOMO-1 NXHhfFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF6Mj64OUDPxE1? NGDvUGZUSU6JRWK=
GI-ME-N MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDvdJJ7UUN3ME2xPFcvQTZ7IN88US=> MWfTRW5ITVJ?
KMS-12-PE NITUbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvTcFA3UUN3ME2xPFkvOjd|IN88US=> M2L1bHNCVkeHUh?=
Daudi M2TXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu5dJhkUUN3ME2xPVEvOTJ6IN88US=> MkLjV2FPT0WU
LB996-RCC M4C3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTFTWM2OD1zOUGuOlk6KM7:TR?= MnTNV2FPT0WU
NCI-H2107 NH\FOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKxTWM2OD1zOUOuO|M6KM7:TR?= NFnLe2pUSU6JRWK=
SK-PN-DW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfqTWM2OD1zOUSuO|E6KM7:TR?= M4LI[HNCVkeHUh?=
MC-CAR NWjnZoxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJyMj6yOVMh|ryP MnrVV2FPT0WU
SNB75 Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfZSFV3UUN3ME2yNlEvQTRizszN NHrLPVFUSU6JRWK=
ES4 NVzOS2drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ{Mz63PFMh|ryP M4[0NnNCVkeHUh?=
KARPAS-422 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\NPXJmUUN3ME2yNlgvOzV{IN88US=> NXvz[WY2W0GQR1XS
NCI-H1648 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ{OT60PFkh|ryP NF;LepZUSU6JRWK=
ES6 NFXhNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\6XWJKSzVyPUKzPU41OyEQvF2= NYrUZXVPW0GQR1XS
KNS-81-FD NHzHO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPwdWZKSzVyPUK0NU4yQTdizszN MoPXV2FPT0WU
JAR M1W3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ3Nj6yNlUh|ryP M4LkfHNCVkeHUh?=
NB1 M33ISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\SWGlEPTB;Mk[wMlUyPiEQvF2= M1HM[HNCVkeHUh?=
D-336MG Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKzSXBOUUN3ME2yOlAvPjl6IN88US=> NYT0W3dbW0GQR1XS
BC-3 M3HFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvWepp6UUN3ME2yOlUvOTd6IN88US=> NWDMPXMxW0GQR1XS
HCC2218 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TE[GlEPTB;Mk[2MlQyPSEQvF2= M4XtWHNCVkeHUh?=
TE-9 NHvWNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\4O|JKSzVyPUK2Ok43OjdizszN MXPTRW5ITVJ?
LB1047-RCC M1vSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTlS2E2UUN3ME2yOlYvPzV|IN88US=> NIP6UG1USU6JRWK=
CTB-1 NEjaVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjHOGxjUUN3ME2yOlkvQTd|IN88US=> NUfuNmNWW0GQR1XS
NB7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHx[VJjUUN3ME2yO|Eh|ryP MnjyV2FPT0WU
ST486 NWXh[ow{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDlNoZKSzVyPUK3O{41OTJizszN MV3TRW5ITVJ?
HCC1187 M4O0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ6Mj64NVEh|ryP M3zjbXNCVkeHUh?=
NCI-SNU-16 NUj6OIVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDT[YdKSzVyPUK4OE4zPDhizszN NGnLXVJUSU6JRWK=
COR-L279 NEDZUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH4ZmtKSzVyPUK5NU42QDRizszN M4PVcnNCVkeHUh?=
ES8 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH1TWM2OD1{OUSuNVgzKM7:TR?= NETzU|NUSU6JRWK=
U-698-M NVL1WFhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInjPYJKSzVyPUK5PE4zPDNizszN NXjBU4U1W0GQR1XS
HEL MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3oO3hKSzVyPUOwPU4yPDlizszN MVfTRW5ITVJ?
KINGS-1 NEGxVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTNzMD62O|Qh|ryP NH3MSHhUSU6JRWK=
KY821 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzyTWM2OD1|M{[uOVk2KM7:TR?= M{XM[3NCVkeHUh?=
MZ1-PC NVrsOFVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTN2NT62NVgh|ryP NWXWXot{W0GQR1XS
LS-411N NH22cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnQ[JhzUUN3ME2zOVQvPjZizszN NE\OcYVUSU6JRWK=
SIG-M5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\lbmlEPTB;M{W5Mlc5OiEQvF2= MkK2V2FPT0WU
HT MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKw[o5PUUN3ME2zOlcvPzFzIN88US=> NV\tRYc4W0GQR1XS
HC-1 M{f5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fhdmlEPTB;M{[3Mlc5PyEQvF2= M3HORXNCVkeHUh?=
NCI-H1694 NI\PN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HCVGlEPTB;M{eyMlk{PCEQvF2= M4CyfXNCVkeHUh?=
BB65-RCC MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP5dFJKSzVyPUO3Ok4zPDVizszN NGjsVmtUSU6JRWK=
HAL-01 NWOy[JFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2we5hKSzVyPUO3PU45OzhizszN NVe0No1DW0GQR1XS
ARH-77 NEfNVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjlTYpwUUN3ME2zPVQvODB6IN88US=> MULTRW5ITVJ?
MZ7-mel MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nBWGlEPTB;M{m3MlI{OyEQvF2= M1f3TXNCVkeHUh?=
SIMA M4T5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRyMz65N|Mh|ryP NGD1W4NUSU6JRWK=
DG-75 NGXpepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTRzNT62PVgh|ryP MkSxV2FPT0WU
HUTU-80 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKxZmI1UUN3ME20NVkvOTh3IN88US=> MVjTRW5ITVJ?
KNS-42 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrMTWM2OD12MkWuPFE2KM7:TR?= MlW5V2FPT0WU
SH-4 NI\5eJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3WmlEPTB;NEK3MlU3PSEQvF2= MoLEV2FPT0WU
L-540 NEfISIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LrVGlEPTB;NEOxMlA{OSEQvF2= NIq1VlhUSU6JRWK=
NB10 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;kW4dlUUN3ME20OFEvOjN2IN88US=> NInxZ|FUSU6JRWK=
ES1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR3Mj63OVMh|ryP MUHTRW5ITVJ?
KMOE-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrMVVZKSzVyPUS1Ok44OTFizszN MnjUV2FPT0WU
MC116 NGjaPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTR3OD6xNVYh|ryP M4L2eHNCVkeHUh?=
RCC10RGB M{P2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR4MD6wNFUh|ryP NILBc2NUSU6JRWK=
RL95-2 NIjqV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPhSoFKSzVyPUS2NE4zOzdizszN NH\5TGNUSU6JRWK=
Raji M4rSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoriTWM2OD12NkiuNVQ{KM7:TR?= M4DIWnNCVkeHUh?=
CAS-1 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWzTWM2OD12N{KuNFc{KM7:TR?= NH;KRmdUSU6JRWK=
Calu-6 NYCycVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[zcWlEPTB;NEe1MlI3PSEQvF2= Mny2V2FPT0WU
KG-1 M4PNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR5OD60OEDPxE1? Mo\iV2FPT0WU
LB771-HNC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR6Mj6yN|Ih|ryP NGjRboFUSU6JRWK=
ACN MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXITWM2OD12OUOuOVk6KM7:TR?= NIP2[ndUSU6JRWK=
KM12 M3;vW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHwdHhKSzVyPUS5Ok42QDlizszN MYrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
NF-κB / Cyclin D1 / MMP2 / MMP9; 

PubMed: 23599805     


Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. 

Gli1 / TGF-β1 / CXCR4; 

PubMed: 26137001     


Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h.

Snail / E-cadherin / Slug / Vimentin ; 

PubMed: 26859575     


SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.

23599805 26137001 26859575
Immunofluorescence
Vimentin; 

PubMed: 24553082     


Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.

PCNA / β-catenin; 

PubMed: 28747625     


Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.

24553082 28747625
In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
- Collapse

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
- Collapse
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine
Smiles CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID